[ad_1]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Convention Name November 6, 2024 4:30 PM ET
Firm Members
Mary Jenkins – Affiliate Director, Investor Relations and Company CommunicationsDouglas Ingram – President and Chief Govt OfficerDallan Murray – Govt Vice President and Chief Buyer OfficerLouise Rodino-Klapac – Govt Vice President, Chief Scientific Officer and Head of Analysis & DevelopmentIan Estepan – Govt Vice President and Chief Monetary Officer
Convention Name Members
Tazeen Ahmad – Financial institution of America Merrill LynchGena Wang – BarclaysAndrew Tsai – JefferiesAnupam Rama – JPMorganDanielle Brill – Raymond JamesEliana Merle – UBSGil Blum – Needham & CompanyRitu Baral – TD CowenJoseph Schwartz – Leerink PartnersKostas Biliouris – BMO Capital MarketsBrian Skorney – BairdKristen Kluska – Cantor FitzgeraldBiren Amin – Piper SandlerGavin Clark-Gartner – Evercore ISILeo Watson – MizuhoSami Corwin – William Blair
Operator
Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Monetary Outcomes Convention Name. After the audio system’ presentation, there will probably be a question-and-answer session. [Operator Instructions] As a reminder, at this time’s convention is being recorded.
Right now, I might now like to show the decision over Mary Jenkins, Affiliate Director, Investor Relations and Company Communications. Please go forward.
Mary Jenkins
Thanks, Michelle, and thanks all for becoming a member of at this time’s name. Earlier this afternoon, we launched our monetary outcomes for the third quarter 2024. The press launch is out there on our web site at sarepta.com, and our 10-Q was filed with the Securities and Alternate Fee this afternoon.
Becoming a member of us on the decision at this time are Doug Ingram; Ian Estepan; Dallan Murray; and Dr. Louise Rodino-Klapac. After our formal remarks, we’ll open the decision for Q&A.
I might like to notice that, throughout this name, we will probably be making a quantity
[ad_2]
Source link
